SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · MED

Sağlıklı asemptomatik LRRK2 mutasyon taşıyıcılarında serebrospinal sıvı ⁇ -sinüklein oligomerlerinin yüksek seviyeleri.

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Makine çevirisi · Editoryal inceleme bekliyor

Front Aging Neurosci · 2014-09-25

DOI: 10.3389/fnagi.2014.00248PMID: 25309429

Open accessresearch-article; Journal ArticleKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Mutations in the leucine-rich repeat kinase 2 gene are the most common cause of autosomal dominant Parkinson's disease (PD). To assess the cerebrospinal fluid (CSF) levels of α-synuclein oligomers in symptomatic and asymptomatic leucine-rich repeat kinase 2 mutation carriers, we used enzyme-linked immunosorbent assays (ELISA) to investigate total and oligomeric forms of α-synuclein in CSF samples. The CSF samples were collected from 33 Norwegian individuals with leucine-rich repeat kinase 2 mutations: 13 patients were clinically diagnosed with PD and 20 patients were healthy, asymptomatic leucine-rich repeat kinase 2 mutation carriers. We also included 35 patients with sporadic PD (sPD) and 42 age-matched healthy controls. Levels of CSF α-synuclein oligomers were significantly elevated in healthy asymptomatic individuals carrying leucine-rich repeat kinase 2 mutations (n = 20; P < 0.0079) and in sPD group (n = 35; P < 0.003) relative to healthy controls. Increased α-synuclein oligomers in asymptomatic leucine-rich repeat kinase 2 mutation carriers showed a sensitivity of 63.0% and a specificity of 74.0%, with an area under the curve of 0.66, and a sensitivity of 65.0% and a specificity of 83.0%, with an area under the curve of 0.74 for sPD cases. An inverse correlation between CSF levels of α- synuclein oligomers and disease severity and duration was observed. Our study suggests that quantification of α-synuclein oligomers in CSF has potential value as a tool for PD diagnosis and presymptomatic screening of high-risk individuals.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.